Cribriform pattern, Genomic Prostate Score, and adverse pathology at radical prostatectomy in a cohort of prostate cancer patients initially on active surveillance.

Authors

Kyle Zuniga

Kyle Brian Zuniga

Osher Center for Integrative Medicine, University of California, San Francisco, San Francisco, CA

Kyle Brian Zuniga , Samuel L. Washington III, Jeffry Simko , Nancy Greenland , Bradley A. Stohr , Janet E. Cowan , Imelda Tenggara , Martina Maggi , June M. Chan , Matthew R. Cooperberg , Peter Carroll

Organizations

Osher Center for Integrative Medicine, University of California, San Francisco, San Francisco, CA, University of California San Francisco, San Francisco, CA, Department of Pathology, University of California, San Francisco, San Francisco, CA, Department of Urology, Sapienza Rome University, Rome, Italy, Department of Epidemiology & Biostatistics, University of California, San Francisco, San Francisco, CA, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

Research Funding

Other

Background: A growing body of literature suggests that the presence of cribriform pattern (CP) in prostate biopsy specimens portends worse outcomes. Furthermore, CP tumors have been found to harbor a myriad of genomic alterations associated with more aggressive disease. We sought to examine the association between CP and Genomic Prostate Score (GPS) and how this association helps predict adverse pathology (AP) at radical prostatectomy (RP) in patients initially managed with active surveillance (AS). Methods: Using the UCSF Urologic Outcomes Database (UODB), we identified 180 AS patients who underwent GPS testing and subsequently RP. Biopsy specimens were re-reviewed centrally to confirm Gleason grade. AP was defined as GS ≥ 4+3, pT3/4, or pN1 on surgical pathology. Clinical and demographic characteristics were compared by CP status using t-tests and chi-squared tests. Cox proportional hazards regression was performed to identify factors associated with AP after adjusting for age, PSA density (log), percentage of positive biopsy cores, biopsy source (UCSF versus outside), and year of diagnosis. Additional models included the base covariates plus presence of CP, GPS, and both CP and GPS. Results: For the cohort, mean age was 60.7 years (SD 7.1) with median PSA of 5.3 ng/ml (interquartile range, IQR 4.2-6.9) at diagnosis. Median PSAD was 0.14 (IQR 0.10-0.20). Among 180 patients, 27 (15%) had CP at biopsy. Mean GPS was significantly higher in CP+ compared to CP- patients (35, SD 12.7 versus 27, SD13.7, p < 0.01), and a greater proportion of CP+ patients had AP compared to CP- (59% versus 54%, p < 0.01). On multivariate analysis, CP was associated with AP (HR 1.9, 95% CI 1.1-3.4, p = 0.02), but significance was lost after adjusting for GPS (p = 0.19). Conclusions: The presence of CP at biopsy was statistically significantly associated with higher GPS. While both were associated with AP at RP, CP was not associated with AP independent of GPS, suggesting an interaction or commonality between these factors not previously explored.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2019 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer,Prostate Cancer

Sub Track

Prostate Cancer - Localized Disease

Citation

J Clin Oncol 37, 2019 (suppl 7S; abstr 88)

DOI

10.1200/JCO.2019.37.7_suppl.88

Abstract #

88

Poster Bd #

E12

Abstract Disclosures